Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | Director | May 20, 2026 | May 23, 2026 |
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | Director | June 15, 2021 | June 17, 2021 |
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Director | May 14, 2026 | May 18, 2026 |
| EyePoint, Inc.EYPT · Entity 5702 | Director | January 06, 2026 | January 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date May 20, 2026 · Filed May 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 18,222 |
Ending reported balance
After 2026-05-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-21 · Exercise / conversion · Acquired 6,142 · Balance 19,697 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. Row 2 · 2026-05-21 · Tax withholding · Disposed 1,475 · Balance 18,222 |
| Non Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.98 · Expires 2036-05-20 | Direct | 11,538 |
Reported balance
After 2026-05-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-20 · Grant · Acquired 11,538 · Balance 11,538 F2: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 5,409 |
Reported balance
After 2026-05-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-20 · Grant · Acquired 5,409 · Balance 5,409 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F2: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-21 · Exercise / conversion · Disposed 6,142 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F3: This award is fully vested in accordance with its terms. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one ordinary share.
F2: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.
F3: This award is fully vested in accordance with its terms.
Aquestive Therapeutics, Inc.
Report date June 15, 2021 · Filed June 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $4.04 · Expires 2031-06-15 | Direct | 20,000 |
Reported balance
After 2021-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-15 · Grant · Acquired 20,000 · Balance 20,000 F1: The shares underlying the options vest as follows: 100% of the underlying shares vest June 15, 2022, subject to Ms. Lurker's continuous service with the Issuer from the grant date through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the options vest as follows: 100% of the underlying shares vest June 15, 2022, subject to Ms. Lurker's continuous service with the Issuer from the grant date through the applicable vesting date.
COLLEGIUM PHARMACEUTICAL, INC
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,758 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 8,741 · Balance 26,758 F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.
EyePoint, Inc.
Report date January 06, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 294,346 |
Reported balance
After 2026-01-06 transaction · row 1
1 source rowRow 1 · 2026-01-06 · Exercise / conversion · Acquired 75,133 · Balance 294,346 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-06 · Exercise / conversion · Disposed 75,133 · Balance 0 F2: The restricted stock units vest in three ratable annual installments beginning January 6, 2024. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 126,889 |
Reported balance
Holding disclosure · report date 2026-01-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 126,889 F1: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2: The restricted stock units vest in three ratable annual installments beginning January 6, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 27, 2020 Filed Jun 30, 2020 23:40 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-004716 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 659,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 20:05 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 14,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001214659-20-005758 · marketforms-49054.xml · derivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 16, 2021, subject to Ms. Lurker's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| June 15, 2020 Filed Feb 11, 2021 21:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 27,132 | $0.00 Strike: $26.50 | $0.00 |
DisclosureSEC source: 0000899243-21-005919 · doc5.xml · derivative · entry 8 Lurker Nancy · CIK 0001450485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 27,132 Underlying: Common Stock · 27,132 shares Expires 2029-02-21 F4 · kind: On June 15, 2020, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on June 25, 2019 and was exercisable for 93,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 27,132 shares of Common Stock of the Company. F8 · derivative.exercise_date: The option vests and becomes exercisable ratably in 48 monthly installments beginning on March 21, 2019. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of May 21, 2020. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until March 21, 2023. F9 · ownership.direct: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 15, 2020 Filed Feb 11, 2021 21:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 27,132 | $0.00 Strike: $26.50 | $0.00 |
DisclosureSEC source: 0000899243-21-005919 · doc5.xml · derivative · entry 7 Lurker Nancy · CIK 0001450485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,868 Underlying: Common Stock · 27,132 shares Expires 2029-02-21 F4 · kind: On June 15, 2020, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on June 25, 2019 and was exercisable for 93,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 27,132 shares of Common Stock of the Company. F8 · derivative.exercise_date: The option vests and becomes exercisable ratably in 48 monthly installments beginning on March 21, 2019. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of May 21, 2020. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until March 21, 2023. Read SEC document |
| June 15, 2020 Filed Feb 11, 2021 21:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0000899243-21-005919 · doc5.xml · derivative · entry 6 Lurker Nancy · CIK 0001450485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-06-14 F3 · kind: On June 15, 2020, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on June 14, 2018 and was exercisable for 54,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 18,000 shares of Common Stock of the Company. F7 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments beginning on June 14, 2019. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of June 14, 2019. The remaining portion of the option retained by the reporting person continues to vest on an annual basis until June 14, 2021. F9 · ownership.direct: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 15, 2020 Filed Feb 11, 2021 21:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0000899243-21-005919 · doc5.xml · derivative · entry 5 Lurker Nancy · CIK 0001450485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 18,000 shares Expires 2028-06-14 F3 · kind: On June 15, 2020, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on June 14, 2018 and was exercisable for 54,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 18,000 shares of Common Stock of the Company. F7 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments beginning on June 14, 2019. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of June 14, 2019. The remaining portion of the option retained by the reporting person continues to vest on an annual basis until June 14, 2021. Read SEC document |
| June 15, 2020 Filed Feb 11, 2021 21:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $17.70 | $0.00 |
DisclosureSEC source: 0000899243-21-005919 · doc5.xml · derivative · entry 4 Lurker Nancy · CIK 0001450485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2027-06-27 F2 · kind: On June 15, 2020, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on December 15, 2017 and was exercisable for 24,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 16,000 shares of Common Stock of the Company. F6 · derivative.exercise_date: The option vested and became exercisable in three equal annual installments beginning on June 27, 2018. At the time of the transfer, the portion of the option that was transferred to the Family Trust had vested in full as of June 27, 2019. The remaining portion of the option retained by the reporting person vested in full as of June 27, 2020. F9 · ownership.direct: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 15, 2020 Filed Feb 11, 2021 21:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $17.70 | $0.00 |
DisclosureSEC source: 0000899243-21-005919 · doc5.xml · derivative · entry 3 Lurker Nancy · CIK 0001450485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 16,000 shares Expires 2027-06-27 F2 · kind: On June 15, 2020, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on December 15, 2017 and was exercisable for 24,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 16,000 shares of Common Stock of the Company. F6 · derivative.exercise_date: The option vested and became exercisable in three equal annual installments beginning on June 27, 2018. At the time of the transfer, the portion of the option that was transferred to the Family Trust had vested in full as of June 27, 2019. The remaining portion of the option retained by the reporting person vested in full as of June 27, 2020. Read SEC document |
| June 15, 2020 Filed Feb 11, 2021 21:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 63,750 | $0.00 Strike: $36.30 | $0.00 |
DisclosureSEC source: 0000899243-21-005919 · doc5.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 63,750 Underlying: Common Stock · 63,750 shares Expires 2026-09-15 F1 · kind: On June 15, 2020, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). The option was originally granted to the reporting person on December 12, 2016 and was exercisable for 85,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 63,750 shares of Common Stock of the Company. F5 · derivative.exercise_date: The option vested and became exercisable in four equal annual installments beginning on September 15, 2017. At the time of the transfer, the portion of the option that was transferred to the Family Trust had vested in full as of September 15, 2019. The remaining portion of the option retained by the reporting person vested in full as of September 15, 2020. F9 · ownership.direct: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 15, 2020 Filed Feb 11, 2021 21:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 63,750 | $0.00 Strike: $36.30 | $0.00 |
DisclosureSEC source: 0000899243-21-005919 · doc5.xml · derivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 Underlying: Common Stock · 63,750 shares Expires 2026-09-15 F1 · kind: On June 15, 2020, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). The option was originally granted to the reporting person on December 12, 2016 and was exercisable for 85,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 63,750 shares of Common Stock of the Company. F5 · derivative.exercise_date: The option vested and became exercisable in four equal annual installments beginning on September 15, 2017. At the time of the transfer, the portion of the option that was transferred to the Family Trust had vested in full as of September 15, 2019. The remaining portion of the option retained by the reporting person vested in full as of September 15, 2020. Read SEC document |
| June 14, 2020 Filed Jun 16, 2020 21:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 45,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-004517 · primarydocument.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On June 14, 2018, the reporting person was granted 135,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F1 · derivative.expiration_date: On June 14, 2018, the reporting person was granted 135,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| June 14, 2020 Filed Jun 16, 2020 21:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-004517 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 619,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 12:40 UTC | EyePoint, Inc. EYPT · Entity 5702 | PurchaseCommon Stock | 98,000 | $1.06 | $104,027.00 |
DisclosureSEC source: 0001562180-20-002379 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 574,800 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.03 to $1.09. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:56 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 748,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001562180-20-002036 · primarydocument.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 748,000 Underlying: Common Stock · 748,000 shares Expires 2030-02-28 F2 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which begin March 28, 2020 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:56 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 374,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-002036 · primarydocument.xml · derivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,000 Underlying: Common Stock · 374,000 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units will vest in three equal installments on the following dates: 6.30.2020, 2.28.2021 and 2.28.2022. F1 · derivative.expiration_date: The restricted stock units will vest in three equal installments on the following dates: 6.30.2020, 2.28.2021 and 2.28.2022. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:50 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 137,174 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-001682 · primarydocument.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,349 Underlying: Common Stock · 137,174 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three ratable annual installments beginning February 21, 2020. F2 · derivative.expiration_date: The restricted stock units vest in three ratable annual installments beginning February 21, 2020. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:50 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 137,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-001682 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 25,171 shares acquired on January 31, 2020 pursuant to EyePoint's 2019 Employee Stock Purchase Plan. Read SEC document |
| October 12, 2019 Filed Oct 15, 2019 22:04 UTC | EyePoint, Inc. EYPT · Entity 5702 | Tax withholdingCommon Stock | 10,745 | $2.11 | $22,618.23 |
DisclosureSEC source: 0001562180-19-005160 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,455 F1 · shares: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of their withholding right following the vesting of the restricted stock units F2 · price: Reflects the last reported sale price for the Registrant's shares of common stock on the Nasdaq Global Market on October 11, 2019 Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 21:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 40,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003675 · primarydocument.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On June 27, 2017, the reporting person was granted 120,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On June 27, 2017, the reporting person was granted 120,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 21:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003675 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 20:50 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 930,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001562180-19-003662 · primarydocument.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 930,000 Underlying: Common Stock · 930,000 shares Expires 2029-02-21 F2 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 21, 2019 Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 20:50 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 411,523 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003662 · primarydocument.xml · derivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,523 Underlying: Common Stock · 411,523 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 21, 2020. F1 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning February 21, 2020. Read SEC document |
| June 14, 2019 Filed Jun 17, 2019 21:42 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 45,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003562 · primarydocument.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 45,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On June 14, 2018, the reporting person was granted 135,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On June 14, 2018, the reporting person was granted 135,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| June 14, 2019 Filed Jun 17, 2019 21:42 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003562 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:47 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 13,350 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001214659-19-004247 · marketforms-45223.xml · derivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,350 Underlying: Common Stock · 13,350 shares Expires 2029-06-13 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 13, 2020, subject to Ms. Lurker's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| March 29, 2019 Filed Apr 1, 2019 12:23 UTC | EyePoint, Inc. EYPT · Entity 5702 | PurchaseCommon Stock | 28,500 | $1.76 | $50,245.50 |
DisclosureSEC source: 0001562180-19-002055 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,200 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.74 to $1.81. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 20:00 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantCommon Stock | 76,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-026783 · doc4.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,700 F1 · shares: On October 12, 2018 (the "FDA Approval Date"), the U.S. Food and Drug Administration approved EyePoint Pharmaceutical Inc.'s (the "Company") new drug application for YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. As a result, 38,334 shares representing a previously granted performance stock unit award vested on that date. An additional 38,333 shares from this award will vest on the first anniversary of the FDA Approval Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date. Read SEC document |
| July 24, 2018 Filed Jul 27, 2018 01:13 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 26,700 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001140361-18-033745 · form4.xml · derivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,700 Underlying: Common Stock · 26,700 shares Expires 2028-07-24 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 25% of the underlying shares vest on the first anniversary of the grant date, 25% of the underlying shares vest on the second anniversary of the grant date and the remaining 50% of the underlying shares vest on the third anniversary of the grant date, subject in each case to Ms. Lurker's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 20:00 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-018707 · doc4.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 40,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 15, 2017, the reporting person was granted 120,000 restricted stock units, vesting in three equal annual installments beginning June 27, 2018. F2 · derivative.expiration_date: On December 15, 2017, the reporting person was granted 120,000 restricted stock units, vesting in three equal annual installments beginning June 27, 2018. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 20:00 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 40,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018707 · doc4.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:06 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (right to buy) · Derivative | 540,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0000899243-18-016980 · doc4.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,000 Underlying: Common Stock · 540,000 shares Expires 2028-06-14 F3 · derivative.exercise_date: The option to purchase will vest and become exercisable in three equal annual installments beginning June 14, 2019. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:06 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 135,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-016980 · doc4.xml · derivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments beginning June 14, 2019. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date. F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments beginning June 14, 2019. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 20:00 UTC | EyePoint, Inc. PSDV · Entity 5702 | GrantCommon stock | 38,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-008244 · doc4.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,033 F1 · shares: On March 19, 2018 (the "NDA Acceptance Date"), the U.S. Food and Drug Administration ("FDA") accepted pSivida Corp.'s (the "Company") new drug application for Durasert 3-year treatment for posterior segment uveitis. As a result, 19,166 shares representing a previously granted performance stock unit award vested on that date. An additional 19,167 shares from this award will vest on the first anniversary of the NDA Acceptance Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 21:18 UTC | EyePoint, Inc. PSDV · Entity 5702 | GrantStock Option (right to buy) · Derivative | 240,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0000899243-17-029169 · doc4.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2027-06-27 F3 · derivative.exercise_date: The option to purchase will vest and become exercisable in three equal annual installments beginning June 27, 2018. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 21:18 UTC | EyePoint, Inc. PSDV · Entity 5702 | GrantRestricted Stock Units · Derivative | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-029169 · doc4.xml · derivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments beginning June 27, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date. F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments beginning June 27, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date. Read SEC document |
| June 14, 2017 Filed Jun 14, 2017 20:05 UTC | EyePoint, Inc. PSDV · Entity 5702 | PurchaseCommon Stock | 56,700 | $1.76 | $99,962.10 |
DisclosureSEC source: 0000899243-17-016365 · doc4.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,700 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.72 to $1.80. The reporting person undertakes to provide pSivida Corp., any security holder of pSivida Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 18:00 UTC | EyePoint, Inc. PSDV · Entity 5702 | GrantEmployee Stock Option (right to buy) · Derivative | 850,000 | $0.00 Strike: $3.63 | $0.00 |
DisclosureSEC source: 0000899243-16-035515 · doc4.xml · derivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,000 Underlying: Common Stock · 850,000 shares Expires 2026-09-15 F1 · derivative.exercise_date: The option becomes exercisable in four equal annual installments beginning on September 15, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.